Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating

William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating on April 8.

Myles Minter has given his Buy rating due to a combination of factors, most notably the strong clinical performance and differentiated profile of claseprubart in autoimmune neurology. Following robust placebo-controlled Phase II results in generalized myasthenia gravis and encouraging early data in CIDP, he views claseprubart as a best-in-class C1s monoclonal antibody, with the added advantage of autoinjector use supporting patient-friendly administration.

Minter also highlights rising conviction in management’s execution, citing how Dianthus has materially narrowed Sanofi’s lead with riliprubart in CIDP to under 18 months, demonstrating effective operational progress. Combined with a catalyst-rich outlook, including the pivotal MoMeNtum readout expected in the second half of 2026 and a logical path for pipeline expansion, these elements underpin his positive stance and support the continued Outperform (Buy) rating on Dianthus shares.

In another report released on April 8, Wolfe Research also maintained a Buy rating on the stock with a $98.00 price target.